Biogen Says QALSODY (tofersen), The First Therapy To Treat Rare, Genetic Form Of ALS, Received Positive Opinion From CHMP
Portfolio Pulse from Benzinga Newsdesk
Biogen announced that QALSODY (tofersen), its therapy for a rare, genetic form of ALS, received a positive opinion from CHMP. The recommendation will be reviewed by the EC for marketing authorization in the EU, with a decision expected in Q2 2024.

February 23, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen's QALSODY receives positive opinion from CHMP for treating a rare form of ALS, awaiting EC decision on EU marketing authorization.
The positive opinion from CHMP for QALSODY represents a significant regulatory milestone for Biogen, potentially leading to market authorization in the EU. This development is likely to be viewed positively by investors, as it opens up a new market for QALSODY, enhancing Biogen's product portfolio and potentially increasing its revenue in the long term. The anticipation of the EC's decision in Q2 2024 may create positive sentiment around Biogen's stock in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90